Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Neoadjuvant chemo for rectal cancer to be applied cautiously

Neoadjuvant chemotherapy before chemoradiation or radiation should be used with caution for advanced rectal cancer, and the latest British Journal of Cancer suggests concurrent chemoradiation with radiotherapy as the best option.

News image

fiogf49gjkf04

Neoadjuvant chemotherapy is a term originally used to describe the administration of chemotherapy preoperatively before surgery.

Neoadjuvant chemotherapy is induced chemotherapy to shrink or downstage a locally advanced tumor.

It thereby facilitates more effective local treatment with surgery or radiotherapy.

The method has been extended with more effective combinations of chemotherapy to reduce the risks of metastatic disease.

It seems logical that survival could be lengthened, or organ preservation rates increased in resectable tumors by neoadjuvant chemotherapy.

In rectal cancer neoadjuvant chemotherapy is being increasingly used in locally advanced and nonmetastatic unresectable tumors.

Randomized studies in advanced colorectal cancer show high response rates to combination cytotoxic therapy.

This evidence of efficacy coupled with the introduction of novel molecular targeted therapies have rekindled an interest in neoadjuvant chemotherapy.

Long waiting times for radiotherapy have also increased interest in delivering neoadjuvant chemotherapy in locally advanced rectal cancer.

In contrast, this enthusiasm is waning for sites such as head and neck, and nasopharynx cancer where traditionally neoadjuvant chemotherapy has been used.

The question arises whether neoadjuvant chemotherapy in rectal cancer a real advance or just history repeating itself.

Dr Glynne-Jones and colleagues from England explored the advantages and disadvantages of the separate approaches of chemotherapy.

The research team undertook a review of neoadjuvant, concurrent and consolidation chemotherapy in locally advanced rectal cancer.

The researchers drew on theoretical principles, preclinical studies and clinical experience both in rectal cancer and other disease sites.

The team found that neoadjuvant chemotherapy may improve outcome in terms of disease-free or overall survival in selected groups in some disease sites.

However, the researchers noted that this strategy has not been shown to be associated with better outcomes than postoperative adjuvant chemotherapy.

Neoadjuvant chemotherapy does not appear to enhance local control
British Journal of Cancer

In particular, the team highlighted that there is insufficient data in rectal cancer.

The evidence for benefit is strongest when neoadjuvant chemotherapy is administered before surgical resection.

In contrast, the data in favour of neoadjuvant chemotherapy before radiation or chemoradiation is inconclusive.

The team noted these findings despite the suggestion that response to induction chemotherapy can predict response to subsequent radiotherapy.

The observation that spectacular responses to chemotherapy before radical radiotherapy did not result in improved survival, was noted 25 years ago.

Multiple trials in head and neck cancer, nasopharyngeal cancer, and non-small-cell lung cancer, do no support the routine use of neoadjuvant chemotherapy.

The researchers also found that trials in small-cell lung cancer and cervical cancer do not support the routine use of neoadjuvant chemotherapy.

The trials identified did not advocate the use of neoadjuvant chemotherapy either as an alternative, or as additional benefit to chemoradiation.

The addition of neoadjuvant chemotherapy does not appear to enhance local control over concurrent chemoradiation or radiotherapy alone.

Dr Glynne-Jones' team concluded, “Neoadjuvant chemotherapy before chemoradiation or radiation should be used with caution, and only in the context of clinical trials.”

“The evidence base suggests that concurrent chemoradiation with early positioning of radiotherapy appears the best option for patients with locally advanced rectal cancer and in all disease sites where radiation is the primary local therapy.”

Br J Canc 2006: 94: 363-71
16 February 2006

Go to top of page Email this page Email this page to a colleague

 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us